BioQuiddity Incorporated, a specialty pharmaceutical company focused on the development and commercialization of large volume ready-to-use infusible pharmaceuticals, and Lee’s Pharmaceutical (HK) Limited, a biopharmaceutical company with over 20 years of operation in Asia, signed a strategic license and supply agreement for the registration and commercialization of BioQuiddity’s ropivacaine and propofol infusion pharmaceutical products in the People’s Republic of China, Taiwan, Hong Kong and Macau.

BioQuiddity’s unit-dose infusible pharmaceuticals are comprised of the pharmaceutical, delivery system and administration line in a self-contained, single use, ready-to-use presentation. The ropivacaine pharmaceutical is prefilled with 0.2% ropivacaine and is intended to provide a safer, more efficient continuous-infusion post-operative pain solution. BioQuiddity’s propofol infusion pharmaceutical features both programable flow and bolus capabilities.

“We are excited to collaborate with Lee’s Pharm as we pursue our goal of setting a new standard of care in the presentation and administration of infusible pharmaceuticals throughout the world,” said Josh Kriesel, president and chief executive officer, BioQuiddity. “Lee’s Pharm’s extensive infrastructure and proven marketing team will be the key in bringing BioQuiddity’s proprietary unit-dose, large volume infusion pharmaceuticals to the Asia Pacific region. We are extremely pleased to add another distinguished partner to our worldwide network.”

Li Xiaoyi, executive director and chief executive officer of Lee’s Pharm, said, “We are honored to partner with BioQuiddity to bring the two unit-dose infusion pharmaceuticals to the Greater China market. BioQuiddity’s infusion pharmaceuticals offer a new and differentiated mode of bringing infusible pharmaceuticals to our customers and to patients.”